8-K: Revvity Reports Mixed Q2 Results, Raises Full-Year EPS Guidance

Revvity announced its second quarter 2024 financial results, reporting a slight revenue decrease but raising its full-year adjusted EPS guidance.

Summary

• Revvity's second quarter 2024 revenue was $692 million, a 2% decrease compared to the same period last year, with a 1% decrease in organic revenue.
• GAAP earnings per share (EPS) were $0.45, up from $0.28 year-over-year, while adjusted EPS from continuing operations was $1.22, slightly up from $1.21.
• The company's GAAP operating income from continuing operations was $86 million, compared to $78 million in the same period last year.
• The Life Sciences segment saw a 7% decrease in reported revenue and a 6% decrease in organic revenue, while the Diagnostics segment reported a 1% increase in revenue and a 3% increase in organic revenue.
• Revvity has updated its full-year 2024 revenue guidance to $2.77-$2.79 billion, reflecting changes in foreign currency exchange rates and assuming 2% organic revenue growth.
• The company also raised its full-year adjusted EPS guidance to a range of $4.70-$4.80.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the raised EPS guidance, but tempered by the revenue decline and mixed segment performance. The company is navigating a challenging market but showing some positive signs.

Positives

• GAAP earnings per share increased to $0.45 from $0.28 year-over-year.
• GAAP operating income from continuing operations increased to $86 million from $78 million year-over-year.
• The Diagnostics segment showed positive growth with a 3% increase in organic revenue.
• The company raised its full-year adjusted EPS guidance to a range of $4.70-$4.80.
• Revvity celebrated its one-year anniversary, highlighting its accomplishments and customer focus.

Negatives

• Total revenue decreased by 2% year-over-year to $692 million.
• Organic revenue decreased by 1% year-over-year.
• The Life Sciences segment experienced a 6% decrease in organic revenue.
• Adjusted operating income decreased to $199 million from $204 million year-over-year.
• Adjusted operating profit margin decreased slightly to 28.7% from 28.8% year-over-year.

Risks

• The company faces risks related to market declines, global economic and political fluctuations, and the failure to introduce new products in a timely manner.
• There are risks associated with acquisitions and divestitures, including the ability to integrate acquired businesses and technologies successfully.
• The company is exposed to risks related to competition, supply chain disruptions, and the loss of key personnel.
• Cybersecurity threats and disruptions to information technology systems pose a risk to the company's operations.
• The company's ability to obtain future financing and comply with regulations are also potential risks.

Future Outlook

The company has updated its full-year 2024 revenue guidance to $2.77-$2.79 billion and raised its adjusted EPS guidance to a range of $4.70-$4.80.

Management Comments

• Prahlad Singh, president and chief executive officer of Revvity, stated that the company's strengths in innovation and execution enabled them to exceed expectations.
• Management believes the company is on a good trajectory towards achieving its full-year goals.

Industry Context

Revvity operates in the health science solutions sector, which includes pharmaceutical, biotech, diagnostic labs, academia, and government customers. The results reflect the current market conditions and the company's performance within this competitive landscape.

Comparison to Industry Standards

• Revvity's performance is mixed when compared to industry peers. While the Diagnostics segment showed positive organic growth, the Life Sciences segment experienced a decline, which is not uncommon in the current economic climate.
• Companies like Thermo Fisher Scientific and Danaher, which also operate in the life sciences and diagnostics space, have reported varying results, with some experiencing similar challenges in certain segments.
• Revvity's adjusted EPS guidance increase is a positive sign, but the revenue decline indicates potential headwinds in the market.
• The company's focus on innovation and execution is a key differentiator, but it needs to address the challenges in the Life Sciences segment to maintain a competitive edge.

Stakeholder Impact

• Shareholders may react positively to the raised EPS guidance but negatively to the revenue decline.
• Employees may be impacted by the company's performance and any potential restructuring or cost-cutting measures.
• Customers may be affected by the company's ability to innovate and deliver products and services.
• Suppliers and creditors may be impacted by the company's financial performance and any changes in its operations.

Next Steps

• The company will discuss its second quarter 2024 results and its outlook for business trends during a webcast on July 29, 2024, at 8:00 a.m. Eastern Time.

Key Dates

Keywords

Revvity, Financial Results, Q2 2024, Earnings Per Share, Revenue, Life Sciences, Diagnostics, EPS Guidance, Organic Growth, Operating Income